Aceto Corp (ACET) 20.17 $ACET
ACETO to Present at the Needham 14th Annual Healthcare Conference
GlobeNewswire - Mon Apr 13, 8:38AM CDT
ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that Sal Guccione, President and CEO, will present at the Needham 14th Annual Healthcare Conference on Tuesday, April 14 at 5:00 p.m. ET. A webcast of the presentation will be available under Events and Presentations in the investor relations section of the company's website at www.aceto.com.
ACET: 20.17 (-0.25)
My Top Health Care Provider And Service Stocks For 2015
Stan Stafford - at Seeking Alpha - Sat Apr 11, 11:31PM CDT
ACHC: 71.98 (-0.47), ACET: 20.17 (-0.25), CTRX: 59.46 (-0.11), MCK: 231.27 (-0.02), BRLI: 35.08 (+0.25), IPCM: 52.02 (-0.06), HLS: 46.35 (+0.48), SEM: 15.29 (+0.27), CI: 130.25 (-0.45), CNC: 70.90 (+0.12), HCA: 77.53 (-0.15), USPH: 48.74 (+0.20), DVA: 83.22 (+0.10), ADUS: 27.60 (-0.33), WCG: 82.65 (-0.33), MD: 73.00 (+0.12), PINC: 37.76 (unch)
Insider Trading Alert - STFC, PGTI And ACET Traded By Insiders
at The Street - Fri Mar 06, 10:00AM CST
Stocks with insider trader activity include STFC, PGTI and ACET
ACET: 20.17 (-0.25), STFC: 23.83 (-0.01), PGTI: 11.49 (+0.02)
Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'
M2 - Tue Mar 03, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcgwrg/the_generic_drugs) has announced the addition of SNS Research's new report "The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" to their offering. A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights. Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs. SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets. The "Generic Drugs Market: 2015 -- 2030 -- Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries. Key Findings: - Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years. - As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan. - In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs. - In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia. - Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020. Key Topics Covered: Chapter 1: Introduction Chapter 2: An Overview of Generic Drugs Chapter 3: Regulatory Landscape Chapter 4: Drug Class Availability & Leading Therapies Chapter 5: Generic Drugs Industry Roadmap & Value Chain Chapter 6: Key Market Players Chapter 7: Market Analysis & Forecasts Chapter 8: Conclusion & Strategic Recommendations Companies Mentioned - ACETO Corporation - AMA (African Medicines Regulatory Agency) - AMRI (Albany Molecular Research, Inc.) - ASKA Pharmaceutical Company - AbbVie - Abbott Laboratories - Acino Holding - Actavis - Actelion - Adcock Ingram - Aesica Pharmaceuticals - Ajinomoto - Akron - Alexion Pharmaceuticals - Alfa Wasserman - Allergan - Almirall - Amgen - Amneal Pharmaceuticals - ApoPharma - Apotex - Arch Pharmalabs - Aspen Holdings - Astellas Pharma - AstraZeneca - Aurobindo Pharma - Auxilium Pharmaceuticals - BD (Becton, Dickinson and Company) - BD Rx - BMS (Bristol-Myers Squibb) For more information visit http://www.researchandmarkets.com/research/xc...eric_drugs Source: SNS Research
AGN: 240.22 (+2.88), ACET: 20.17 (-0.25), ABT: 48.35 (+1.23), AUXL: 36.47 (-0.06), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), BMY: 66.60 (-0.21), AMRI: 18.48 (-0.19)
2015 New-Year Coverage Universe Updates
DAG Investments - at Seeking Alpha - Thu Feb 12, 9:10AM CST
ACET: 20.17 (-0.25), GE: 26.91 (+0.29), KR: 70.39 (-1.44), BX: 41.76 (+0.04), CCLP: 20.70 (+0.21), CECE: 11.63 (+0.01), PFE: 34.93 (+0.04), HAL: 47.11 (+0.06), SPWR: 34.74 (+0.28), HLS: 46.35 (+0.48), MTW: 19.99 (+0.39), AET: 107.95 (-0.41), MWA: 10.26 (+0.27), VLO: 59.35 (+1.02), FSLR: 63.88 (+0.77), WBA: 87.02 (-0.07), RJF: 57.00 (+0.22), TRN: 32.82 (-3.43), CWCO: 12.15 (-0.05), WMB: 52.56 (+1.01), ANAC: 66.45 (-0.22), SXI: 82.53 (+0.12), IHG: 42.82 (-0.08)
Aceto's (ACET) CEO Salvatore Guccione on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 06, 11:42AM CST
ACET: 20.17 (-0.25)
Aceto beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 4:04PM CST
ACET: 20.17 (-0.25)
ACETO Reports Second Quarter Fiscal 2015 Results
GlobeNewswire - Thu Feb 05, 4:00PM CST
ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, announced today financial results for the second quarter of fiscal 2015 ended December 31, 2014.
ACET: 20.17 (-0.25)
Aceto declares $0.06 dividend
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 2:40PM CST
ACET: 20.17 (-0.25)
ACETO Board of Directors Declares Quarterly Cash Dividend
GlobeNewswire - Thu Feb 05, 2:34PM CST
ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that its Board of Directors has declared a regular quarterly dividend of $0.06 per common share. This quarterly cash dividend will be distributed on March 26, 2015 to shareholders of record as of March 12, 2015.
ACET: 20.17 (-0.25)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 4:35PM CST
BEBE: 3.26 (-0.05), ACET: 20.17 (-0.25), ARCW: 7.06 (-0.57), CPST: 0.64 (+0.01), AIV: 38.63 (+0.70), DV: 36.49 (+0.22), EGAN: 3.35 (-0.05), CUTR: 13.98 (-0.01), MTD: 324.14 (+0.66), PXLW: 5.03 (-0.02), LNKD: 259.35 (+0.93), ADNC: 5.92 (+0.05), LGF: 31.24 (+0.10), AHL: 48.21 (+0.07), HME: 68.48 (+0.68), PDFS: 18.81 (-0.02), MCK: 231.27 (-0.02), KRG: 27.39 (-0.19), ATHN: 120.16 (-1.35), PCTY: 31.29 (+0.64), BRS: 60.14 (+0.21), ECOM: 10.52 (+0.09), FWM: 6.31 (+0.04), EXPE: 99.47 (+1.16), NTGR: 33.15 (+0.57), IMPV: 47.68 (-0.88), OLN: 31.10 (-0.04), MRIN: 6.39 (+0.01), BWLD: 175.05 (-3.76), ASYS: 12.01 (+0.40), DCT: 33.44 (+0.02), BCOV: 6.87 (+0.06), MXWL: 6.94 (-0.13), CME: 90.67 (+0.43), ATVI: 23.49 (+0.10), KIM: 25.17 (-0.13), P: 17.51 (+0.28), BMI: 62.60 (+0.78), OUTR: 69.37 (+0.49), CTRL: 12.29 (-0.16), GPRO: 46.25 (+1.94), ECHO: 33.39 (+1.37), RDEN: 14.91 (-0.09), NUAN: 14.26 (+0.10), ATR: 62.88 (+0.16), ACLS: 2.64 (unch), EGOV: 17.81 (+0.04), PDM: 18.07 (+0.04), FLDM: 43.04 (-1.36), BRKS: 11.23 (-0.04), FLT: 158.25 (+0.01), ASEI: 49.27 (+0.35), ENH: 61.61 (+0.22), CALD: 13.36 (-0.11), ONNN: 11.70 (+0.22), LF: 2.27 (+0.01)
Commit To Purchase Aceto Corp. At $17.50, Earn 9.7% Annualized Using Options
at The Street - Thu Jan 29, 10:38AM CST
Investors eyeing a purchase of Aceto Corp. stock, but cautious about paying the going market price of $19.89/share, might benefit from considering selling puts among the alternative strategies at their disposal.
ACET: 20.17 (-0.25)
ACETO Corporation Schedules Second Quarter Fiscal 2015 Financial Results News Release and Conference Call
GlobeNewswire - Mon Jan 26, 9:03AM CST
ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, will issue its financial results of operations for the second quarter of fiscal 2015 ended December 31, 2014 after the stock market close on Thursday, February 5, 2015.
ACET: 20.17 (-0.25)
United States Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry Analytics 2014-2021 - Market to reach $21.2 billion by 2021
M2 - Mon Dec 15, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/b7xlml/vitamins) has announced the addition of Plunkett Research Ltd's new report "Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.) to reach $21.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - Aceto Corporation - Balchem Corp - Cambrex Corp - Mannatech Inc - Mead Johnson Nutrition Company - NBTY Inc - Schiff Nutrition International Inc - Sigma-Aldrich Corp - Synutra International, Inc. - USANA Health Sciences Inc For more information visit http://www.researchandmarkets.com/research/b7xlml/vitamins Source: Plunkett Research Ltd
ACET: 20.17 (-0.25), MJN: 98.92 (-1.00), CBM: 42.07 (-0.65), SIAL: 138.92 (+0.17), USNA: 123.36 (+2.82), SYUT: 7.61 (-0.01), MTEX: 20.83 (+0.14), BCPC: 55.72 (-1.00)
Insider Trading Alert - GLT, NEWT And ACET Traded By Insiders
at The Street - Fri Dec 12, 10:00AM CST
Stocks with insider trader activity include GLT, NEWT and ACET
ACET: 20.17 (-0.25), NEWT: 17.18 (+0.04), GLT: 25.56 (-0.30)
Update: Aceto Corporation SIC Code Change
DAG1996 - at Seeking Alpha - Wed Dec 10, 12:16AM CST
ACET: 20.17 (-0.25)
Aceto Corporation declares $0.06 dividend
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 4:01PM CST
ACET: 20.17 (-0.25)
ACETO Receives SEC Approval to Change its SIC Code to 5122
GlobeNewswire - Thu Dec 04, 10:52AM CST
ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that the Securities and Exchange Commission has approved the Company's request to change its SIC code from 5160, Wholesale - Chemicals and Allied Products, to 5122, Wholesale- Drugs, Proprietaries and Druggists' Sundries, effective immediately.
ACET: 20.17 (-0.25)
Insider Trading Alert - ACET, VG And RIBT Traded By Insiders
at The Street - Wed Dec 03, 10:30AM CST
Stocks with insider trader activity include ACET, VG and RIBT
ACET: 20.17 (-0.25), RIBT: 3.89 (+0.04), VG: 4.91 (-0.05)
ACETO to Present at the Needham 14th Annual Healthcare Conference
GlobeNewswire - Mon Apr 13, 8:38AM CDT
ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that Sal Guccione, President and CEO, will present at the Needham 14th Annual Healthcare Conference on Tuesday, April 14 at 5:00 p.m. ET. A webcast of the presentation will be available under Events and Presentations in the investor relations section of the company's website at www.aceto.com.
ACET: 20.17 (-0.25)
My Top Health Care Provider And Service Stocks For 2015
Stan Stafford - at Seeking Alpha - Sat Apr 11, 11:31PM CDT
ACHC: 71.98 (-0.47), ACET: 20.17 (-0.25), CTRX: 59.46 (-0.11), MCK: 231.27 (-0.02), BRLI: 35.08 (+0.25), IPCM: 52.02 (-0.06), HLS: 46.35 (+0.48), SEM: 15.29 (+0.27), CI: 130.25 (-0.45), CNC: 70.90 (+0.12), HCA: 77.53 (-0.15), USPH: 48.74 (+0.20), DVA: 83.22 (+0.10), ADUS: 27.60 (-0.33), WCG: 82.65 (-0.33), MD: 73.00 (+0.12), PINC: 37.76 (unch)
Insider Trading Alert - STFC, PGTI And ACET Traded By Insiders
at The Street - Fri Mar 06, 10:00AM CST
Stocks with insider trader activity include STFC, PGTI and ACET
ACET: 20.17 (-0.25), STFC: 23.83 (-0.01), PGTI: 11.49 (+0.02)
Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'
M2 - Tue Mar 03, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/xcgwrg/the_generic_drugs) has announced the addition of SNS Research's new report "The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" to their offering. A generic drug is a pharmaceutical product, usually intended to be interchangeable with an innovator product, that is manufactured without a license from the innovator company and marketed after the expiry date of the patent or other exclusive rights. Already prevalent in the U.S., Europe and much of the developing world, generic drugs are now finding their way into previously untapped markets such as Japan, largely driven by regulatory efforts to reduce healthcare costs. SNS Research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. The market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets. The "Generic Drugs Market: 2015 -- 2030 -- Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs ecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents market size forecasts for generic drugs from 2015 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries. Key Findings: - Generic drugs will account for nearly $350 Billion in revenue by the end of 2015. The market is further expected to grow at a CAGR of 12% over the next five years. - As the market consolidates, larger players continue to grow their market share on the heels of acquisitions and mergers. Well established players are particularly keen to capitalize on joint ventures in untapped markets such as Japan. - In order to overcome low margins, some generic drug manufacturers are venturing into the super generics opportunity. Sold for a significantly higher price than their pure generic counterparts, super generics account for 18% of all spending on generic drugs. - In a bid to control costs and expand their global reach, generic drug manufacturers are complementing their existing manufacturing and R&D locations with sites in low cost countries such as India, China and Russia. - Driven by the cost saving potential of biosimilar drugs, a number of countries have established regulatory pathways for their approval. We estimate that approved biosimilar drugs will account for more than $20 Billion in revenue by the end of 2020. Key Topics Covered: Chapter 1: Introduction Chapter 2: An Overview of Generic Drugs Chapter 3: Regulatory Landscape Chapter 4: Drug Class Availability & Leading Therapies Chapter 5: Generic Drugs Industry Roadmap & Value Chain Chapter 6: Key Market Players Chapter 7: Market Analysis & Forecasts Chapter 8: Conclusion & Strategic Recommendations Companies Mentioned - ACETO Corporation - AMA (African Medicines Regulatory Agency) - AMRI (Albany Molecular Research, Inc.) - ASKA Pharmaceutical Company - AbbVie - Abbott Laboratories - Acino Holding - Actavis - Actelion - Adcock Ingram - Aesica Pharmaceuticals - Ajinomoto - Akron - Alexion Pharmaceuticals - Alfa Wasserman - Allergan - Almirall - Amgen - Amneal Pharmaceuticals - ApoPharma - Apotex - Arch Pharmalabs - Aspen Holdings - Astellas Pharma - AstraZeneca - Aurobindo Pharma - Auxilium Pharmaceuticals - BD (Becton, Dickinson and Company) - BD Rx - BMS (Bristol-Myers Squibb) For more information visit http://www.researchandmarkets.com/research/xc...eric_drugs Source: SNS Research
AGN: 240.22 (+2.88), ACET: 20.17 (-0.25), ABT: 48.35 (+1.23), AUXL: 36.47 (-0.06), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), BMY: 66.60 (-0.21), AMRI: 18.48 (-0.19)
2015 New-Year Coverage Universe Updates
DAG Investments - at Seeking Alpha - Thu Feb 12, 9:10AM CST
ACET: 20.17 (-0.25), GE: 26.91 (+0.29), KR: 70.39 (-1.44), BX: 41.76 (+0.04), CCLP: 20.70 (+0.21), CECE: 11.63 (+0.01), PFE: 34.93 (+0.04), HAL: 47.11 (+0.06), SPWR: 34.74 (+0.28), HLS: 46.35 (+0.48), MTW: 19.99 (+0.39), AET: 107.95 (-0.41), MWA: 10.26 (+0.27), VLO: 59.35 (+1.02), FSLR: 63.88 (+0.77), WBA: 87.02 (-0.07), RJF: 57.00 (+0.22), TRN: 32.82 (-3.43), CWCO: 12.15 (-0.05), WMB: 52.56 (+1.01), ANAC: 66.45 (-0.22), SXI: 82.53 (+0.12), IHG: 42.82 (-0.08)
Aceto's (ACET) CEO Salvatore Guccione on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 06, 11:42AM CST
ACET: 20.17 (-0.25)
Aceto beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 4:04PM CST
ACET: 20.17 (-0.25)
ACETO Reports Second Quarter Fiscal 2015 Results
GlobeNewswire - Thu Feb 05, 4:00PM CST
ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, announced today financial results for the second quarter of fiscal 2015 ended December 31, 2014.
ACET: 20.17 (-0.25)
Aceto declares $0.06 dividend
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 2:40PM CST
ACET: 20.17 (-0.25)
ACETO Board of Directors Declares Quarterly Cash Dividend
GlobeNewswire - Thu Feb 05, 2:34PM CST
ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that its Board of Directors has declared a regular quarterly dividend of $0.06 per common share. This quarterly cash dividend will be distributed on March 26, 2015 to shareholders of record as of March 12, 2015.
ACET: 20.17 (-0.25)
Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 4:35PM CST
BEBE: 3.26 (-0.05), ACET: 20.17 (-0.25), ARCW: 7.06 (-0.57), CPST: 0.64 (+0.01), AIV: 38.63 (+0.70), DV: 36.49 (+0.22), EGAN: 3.35 (-0.05), CUTR: 13.98 (-0.01), MTD: 324.14 (+0.66), PXLW: 5.03 (-0.02), LNKD: 259.35 (+0.93), ADNC: 5.92 (+0.05), LGF: 31.24 (+0.10), AHL: 48.21 (+0.07), HME: 68.48 (+0.68), PDFS: 18.81 (-0.02), MCK: 231.27 (-0.02), KRG: 27.39 (-0.19), ATHN: 120.16 (-1.35), PCTY: 31.29 (+0.64), BRS: 60.14 (+0.21), ECOM: 10.52 (+0.09), FWM: 6.31 (+0.04), EXPE: 99.47 (+1.16), NTGR: 33.15 (+0.57), IMPV: 47.68 (-0.88), OLN: 31.10 (-0.04), MRIN: 6.39 (+0.01), BWLD: 175.05 (-3.76), ASYS: 12.01 (+0.40), DCT: 33.44 (+0.02), BCOV: 6.87 (+0.06), MXWL: 6.94 (-0.13), CME: 90.67 (+0.43), ATVI: 23.49 (+0.10), KIM: 25.17 (-0.13), P: 17.51 (+0.28), BMI: 62.60 (+0.78), OUTR: 69.37 (+0.49), CTRL: 12.29 (-0.16), GPRO: 46.25 (+1.94), ECHO: 33.39 (+1.37), RDEN: 14.91 (-0.09), NUAN: 14.26 (+0.10), ATR: 62.88 (+0.16), ACLS: 2.64 (unch), EGOV: 17.81 (+0.04), PDM: 18.07 (+0.04), FLDM: 43.04 (-1.36), BRKS: 11.23 (-0.04), FLT: 158.25 (+0.01), ASEI: 49.27 (+0.35), ENH: 61.61 (+0.22), CALD: 13.36 (-0.11), ONNN: 11.70 (+0.22), LF: 2.27 (+0.01)
Commit To Purchase Aceto Corp. At $17.50, Earn 9.7% Annualized Using Options
at The Street - Thu Jan 29, 10:38AM CST
Investors eyeing a purchase of Aceto Corp. stock, but cautious about paying the going market price of $19.89/share, might benefit from considering selling puts among the alternative strategies at their disposal.
ACET: 20.17 (-0.25)
ACETO Corporation Schedules Second Quarter Fiscal 2015 Financial Results News Release and Conference Call
GlobeNewswire - Mon Jan 26, 9:03AM CST
ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, will issue its financial results of operations for the second quarter of fiscal 2015 ended December 31, 2014 after the stock market close on Thursday, February 5, 2015.
ACET: 20.17 (-0.25)
United States Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry Analytics 2014-2021 - Market to reach $21.2 billion by 2021
M2 - Mon Dec 15, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/b7xlml/vitamins) has announced the addition of Plunkett Research Ltd's new report "Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.) to reach $21.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - Aceto Corporation - Balchem Corp - Cambrex Corp - Mannatech Inc - Mead Johnson Nutrition Company - NBTY Inc - Schiff Nutrition International Inc - Sigma-Aldrich Corp - Synutra International, Inc. - USANA Health Sciences Inc For more information visit http://www.researchandmarkets.com/research/b7xlml/vitamins Source: Plunkett Research Ltd
ACET: 20.17 (-0.25), MJN: 98.92 (-1.00), CBM: 42.07 (-0.65), SIAL: 138.92 (+0.17), USNA: 123.36 (+2.82), SYUT: 7.61 (-0.01), MTEX: 20.83 (+0.14), BCPC: 55.72 (-1.00)
Insider Trading Alert - GLT, NEWT And ACET Traded By Insiders
at The Street - Fri Dec 12, 10:00AM CST
Stocks with insider trader activity include GLT, NEWT and ACET
ACET: 20.17 (-0.25), NEWT: 17.18 (+0.04), GLT: 25.56 (-0.30)
Update: Aceto Corporation SIC Code Change
DAG1996 - at Seeking Alpha - Wed Dec 10, 12:16AM CST
ACET: 20.17 (-0.25)
Aceto Corporation declares $0.06 dividend
Seeking Alpha - at Seeking Alpha - Thu Dec 04, 4:01PM CST
ACET: 20.17 (-0.25)
ACETO Receives SEC Approval to Change its SIC Code to 5122
GlobeNewswire - Thu Dec 04, 10:52AM CST
ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sale and distribution of products for Human Health, Pharmaceutical Ingredients and Performance Chemicals, today announced that the Securities and Exchange Commission has approved the Company's request to change its SIC code from 5160, Wholesale - Chemicals and Allied Products, to 5122, Wholesale- Drugs, Proprietaries and Druggists' Sundries, effective immediately.
ACET: 20.17 (-0.25)
Insider Trading Alert - ACET, VG And RIBT Traded By Insiders
at The Street - Wed Dec 03, 10:30AM CST
Stocks with insider trader activity include ACET, VG and RIBT
ACET: 20.17 (-0.25), RIBT: 3.89 (+0.04), VG: 4.91 (-0.05)
